In conclusion, we used an experimental approach that mimics the prostate tumours in their physiological environment and points out a concrete clinical application for prostate cancer therapy based on TMPRSS2-ERG knockdown. The gene discussed is TMPRSS2; the disease is prostate carcinoma.